FDA international memorandum of understanding policy formalized.
This article was originally published in The Gray Sheet
Executive Summary
FDA MEMORANDUM OF UNDERSTANDING POLICY FORMALIZED in a compliance policy guide published in the June 15 Federal Register. Formulated in response to a recommendation in a December 1992 report of the agency's International Harmonization Task Force ("The Gray Sheet" Jan. 25, 1993, p. 6), the policy outlines general principles for developing MOUs with foreign governments and international organizations, as well as procedures for initiating and monitoring such agreements.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.